In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.

The interesting in vitro antimicrobial activity and pharmacokinetics of the new quinolone trovafloxacin (CP-99,219) warranted further studies to determine its in vivo efficacy in models of infectious disease. The significance of the pharmacokinetic and in vitro antimicrobial profiles of trovafloxaci...

Ausführliche Beschreibung

Bibliografische Detailangaben

Veröffentlicht in:	Antimicrob Agents Chemother
Hauptverfasser:	Girard, A E, Girard, D, Gootz, T D, Faiella, J A, Cimochowski, C R
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	American Society for Microbiology (ASM) 1995
Schlagworte:	Research Article
Online-Zugang:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC162916/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8619569/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.39.10.2210
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!